SAGA Diagnostics AB ("SAGA"), a cancer liquid biopsy and genomic testing company, today announced that it has raised SEK 106 million (€10.5 million) in a Series A2 financing from both existing and new investors. The Series A2 round was led by Segulah Medical Acceleration and the Sciety investment syndicate with strong support from existing shareholders such as Hadean Ventures.

The company already has commercial agreements with a number of pharmaceutical partners, key opinion leaders, and clinical laboratories for the use of these technologies, both as laboratory testing service and sold as reagent kits. SAGA Diagnostics' technology allows the company to develop diagnostic tests for various cancers with the possibility to improve patient survival and quality of life."

Saga Diagnostics Raises Sek 106 Million (€10.5 Million) To Accelerate Commercialization Of Ultrasensitive Cancer Liquid Biopsies

Description

Company Information

Funding Insights

Saga Diagnostics Raises Sek 106 Million (€10.5 Million) To Accelerate Commercialization Of Ultrasensitive Cancer Liquid Biopsies

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information